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Several technologies have been developed to isolate human antibodies against different 
target antigens as a source of potential therapeutics, including hybridoma technology, 
phage and yeast display systems. For conventional antibodies, this involves either random 
pairing of VH and variable light (VL) domains in combinatorial display libraries or isolation 
of cognate pairs of VH and VL domains from human B cells or from transgenic mice 
carrying human immunoglobulin loci followed by single-cell sorting, single-cell RT-PCR, 
and bulk cloning of isolated natural VH–VL pairs. Heavy-chain-only antibodies (HCAbs) 
that naturally occur in camelids require only heavy immunoglobulin chain cloning. Here, 
we present an automatable novel, high-throughput technology for rapid direct cloning 
and production of fully human HCAbs from sorted population of transgenic mouse 
plasma cells carrying a human HCAb locus. Utility of the technique is demonstrated by 
isolation of diverse sets of sequence unique, soluble, high-affinity influenza A strain X-31 
hemagglutinin-specific HCAbs.
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InTRoDUcTIon
Camelidae produce not only conventional antibodies, composed of two heavy and two light 
chains (H2L2), but also antibodies composed of heavy chains only. Although in the conventional 
antibodies both chains contribute to the antigen binding site, the antigen binding site of camelid 
heavy-chain-only antibodies (HCAbs) is formed by single heavy chain variable domain (VHH) 
(1, 2). We have previously generated transgenic mice containing hybrid llama-human antibody loci 
with two llama variable VHH regions and human D, J, and Cµ and/or Cγ constant regions. Such loci 
rearrange productively and rescue B cell development efficiently (3).
Heavy-chain-only antibodies are expressed at high levels in camelids (4) and in transgenic mice 
(3, 5), provided that the CH1 domain is deleted from the constant regions. HCAb production does 
not require an IgM stage for effective pre-B cell signaling, and antigen-specific heavy-chain-only 
IgGs are produced upon immunization (3). Camelid VHH segments are soluble and this is attributed 
to the presence of a germ line-encoded tetrad of specific hydrophilic amino acid substitutions at the 
hydrophobic interface of the conventional VH domain that normally interacts with a variable light 
FIgURe 1 | Schematic representation of the procedure leading to 
heavy-chain-only antibody (hcAb) production with human hcAb 
locus construct used for transgenesis. It carries 4VH regions, all of the 
human D and J regions and the Cγ2 and Cγ3 regions lacking the CH1 
domain.
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chain domain (VL) (6) and a CDR3 loop that folds over the VHH, 
covering the side of the domain that normally interacts with a VL 
domain (7).
In contrast, human VH domains usually aggregate and are less 
stable due to exposure of the hydrophobic amino acids at the for-
mer interface (8) and the loss of contacts between the V regions, 
respectively. This limits their applicability [see Rosenberg (9) and 
Fahrner et al. (10)]. However, extensive engineering and selection 
(7, 8) mainly by increasing the hydrophilicity of the VH domain 
(8) and by replacing exposed hydrophobic residues in the CDR3 
region (7) will increase the solubility of the VH domain. These 
methods have the disadvantage that they require extensive work 
and that amino acid changes particularly in the CDR3 region 
could reduce or change the specificity and affinity of antigen 
binding.
We hypothesized that the mouse would be much more effec-
tive at such engineering in vivo through the natural process of 
selection. We, therefore, introduced a fully human HCAb locus 
into mice to generate fully human HCAbs of different classes 
or fragments thereof in response to antigen challenge for use as 
therapeutic agents in man. To this end, we replaced the llama 
VHH domains with human VH domains in the transgenic 
construct used by Janssens et  al. (3), generated a number of 
transgenic lines, and derived a number of HCAb against differ-
ent antigens by hybridoma and phage display technology. Both 
the hybridoma and phage display technologies have a number of 
disadvantages, are quite laborious, and in addition phage display 
needs additional full-format HCAb recloning in eukaryotic 
systems.
It has been known that long-term production of Abs is 
maintained by a combination of short-lived and long-lived 
plasma cells (PCs), usually defined functionally as Ab-secreting 
cells (ASC). Although short-lived ASC die within 3–5 days, Ab 
levels can be maintained by continuous proliferation and dif-
ferentiation of memory B cells (MBC) into short-lived ASC upon 
continuous reactivation (11, 12), such as persistent antigen expo-
sure. Alternatively, long-term production of Ab is maintained by 
long-lived ASC, which migrate to survival niches within the bone 
marrow (13, 14) and spleen (15). Thus, we used CD138+ CD45R 
B220low/− CD19low/− antibody-secreting PCs (16), bone marrow, 
and spleen of immunized mice containing a human HCAb locus 
(4HVH) as the enriched RNA source for the production of an 
expression library.
Here, we describe an automatable alternative method for 
rapid cloning and identification of antigen-specific HCAbs from 
immunized transgenic mice (4HVH) carrying a fully human 
heavy chain locus by cloning the VDJ region of the HCAb cDNA 
directly into a mammalian expression vector and identifying the 
human embryonic kidney 293  T (HEK293T) clones secreting 
antigen-specific HCAb (See Figure 1).
MeThoDS
Immunization
4HVH transgenic mice and control wild-type (WT) mice were 
immunized according to the protocol approved by the Dutch 
Experimental animal committee DEC Nr EUR 1944. Briefly, 
mice were injected i.p. five times at 2-week intervals with the 
influenza virus X-31 hemagglutinin (HA), prepared as described 
by Ruigrok et al. (17), and dissolved in phosphate-buffered saline 
(PBS) at pH 7.4 using Stimune adjuvant (Prionics, Switzerland) 
according to the formulation provided by the supplier. The last 
injection was without the adjuvant. Four days after the last injec-
tion, 4HVH mice were sacrificed and PCs isolated.
pc Isolation and library construction
A single-cell suspension was prepared from spleens and 
femurs in 0.5% BSA, 2 mM EDTA in PBS. Cells were counted 
(Burke chamber), and magnetic cell sorting of CD138+ cells was 
performed using mouse CD138+ plasma isolation kit (Miltenyi 
Biotec GmbH, Germany) according to the manufacturer’s 
instructions. Basically, this consists of two steps: first a depletion 
of non-PCs by indirect magnetic labeling of CD49b and CD45R 
FIgURe 2 | Schematic representation of the pcAghygro g2 and the 
pcAghygro g3 eukaryotic expression vectors used to generate the 
heK293T cell libraries.
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cells with a non-PC depletion cocktail and anti-biotin microBe-
ads followed by magnetic separation using LD columns (Miltenyi 
Biotec GmbH, Germany), and the next step is a positive selection 
of PCs by direct labeling with CD138 MicroBeads followed by 
magnetic separation on a MS column (Miltenyi Biotec GmbH, 
Germany). PCs eluted from the column were spun down and 
the pellet resuspended in 400  µl of Ultraspec™ RNA reagent 
(Biotecx laboratories, Inc., Houston, TX, USA). Total RNA was 
made according to the manufacturer’s instructions. The RNA was 
dissolved in 20 µl of dH2O and 3 µg was used in a 20 µl reaction 
volume for a first strand cDNA synthesis using SuperScript™ 
II RT (Invitrogen by Fisher Scientific, USA) according to the 
instructions using oligo dT priming with oligo (dT) 12-18 
primer (Invitrogen by Life Technologies, USA). The transgenic 
mice contain four different VHs (1-46, 3-11, 3-53, and 3-23), and 
hence three different leader-specific primers were designed for 
the 5′-end. All of them contained a PvuII site that is unique in 
the final expression vectors (pCAG hygro G2 and pCAG hygro 
G3 containing leader sequence from VH3-23). The following 
5′-primers were used:
lib-3-23/53-S: 5′-GTGTCCAGTGTGAGGTGCAGCTG-3′,
lib-3-11-S: 5′-GTGTCCAGTGTCAGGTGCAGCTG-3′, and
lib-1-46-S: 5′-GTGCTCACTCCCAGGTGCAGCTG.
For the 3′-end, we used primer HINGEIgG2rv [previously used 
and described for phage display library (3)] and HINGEIgG3rv: 
5′-AATTGTGTGAGCGGCCGCACCAAGTGGGGTTTT 
GAGCTC.
An additional 3′-end primer was used: lib-IgG2/3-CH3-AS: 
5′-CTGACCTGGTTCTTGGTCATCTCCTC.
This primer from the CH3 constant region is common for both 
G2 and G3. However, in combination with any of the 5′-primers, 
it amplifies only IgG2. To make sure that all of the VHs were 
represented in the library, each of the 5′-end primers was used 
separately in combination with each of the 3′-end primers, 
and the products were mixed in an equimolar ratio later. PCR 
was performed with high-fidelity DNA polymerase Phusion™ 
(New England Biolabs, Inc., USA) using cycling conditions 
recommended by the manufacturer for the three-step protocol 
with an annealing temperature of 68°C and 35 cycles in total. 
PCR products for IgG2 were cut either with PvuII/BstEII or 
PvuII/BsrGI (unique site in the constant region) if the ampli-
fied fragment originated from using the combination with the 
Lib-IgG2/3-CH3 primer and cloned into PvuII/BstEII or 
PvuII/BsrGI cut and phosphatase-treated pCAGhygro G2 vector.
PCR products for IgG3 were digested with PvuII/BstEII or 
PvuII/SacI and cloned into PvuII/BstEII cut and phosphatase-
treated pCAGhygro G2 or PvuII/SacI cut and phosphatase-
treated pCAGhygro G3 vector.
pCAGhygro G2 and pCAG hygro G3 are depicted in Figure 2. 
In short, the vector contains an ampicillin resistance gene for 
bacteria selection and a hygromycin resistance for the eukaryotic 
cell selection. The HCAb expression is driven by ubiquitous CMV 
enhancer and chicken beta actin promoter. The human VH 3-23 
leader is responsible for secretion of the antibody. Constant 
regions have a deleted CH1 exon.
Transformation, plasmid preparation, and 
Transfection into heK 293T cells
All ligations were done overnight at 16°C in 10 µl total volume 
using 120  ng of vector alone (control) or in combination with 
30  ng of insert using T4DNA ligase (Promega, Madison, WI, 
USA). Ligations were diluted 5× (40 µl of dH2O into 10 µl liga-
tion), and 1 µl was used to transform 20 µl of electrocompetent 
MegaX DH10B™ T1® cells (Invitrogen by Life Technologies, 
Grand Island, NY, USA) according to the instructions provided 
by the manufacturer.
Plating was done on 2XTY/Amp agar plates, and 960 indi-
vidual colonies were picked into 1.5 ml of 2XTY/Amp medium 
in 96-well format. A total of 960 DNA plasmid preparations 
were done using NucleoSpin R96 flash (Macherey-Nagel, 
Germany) designed for rapid manual and automated 96-well 
DNA preparation of high- and low-copy plasmid and Bac DNA 
from Escherichia coli. Each DNA was dissolved in 50 µl sterile 
dH2O. A total of 200 ng of DNA (estimated to be in10 µl of DNA 
preparations based on random sample concentration measure-
ments) was used for transfection into HEK 293T cells. The HEK 
293T cells were plated into 96-well plates and transfected using 
Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions for 96-well format. The 
following day, medium was removed and replaced with DMEM 
medium (Lonza, Belgium) supplemented with hygromycin 
(Roche, Diagnostics GmbH, Germany) at a concentration of 
200 µg/ml, non-essential amino acids (NEAA, Lonza, Belgium), 
and 10% fetal calf serum (FCS). On day 4 posttransfection, 100 µl 
of medium was taken from each well for an antigen-specific 
enzyme-linked immunosorbent assay (ELISA) and replaced with 
a fresh medium.
elISA Assay
Enzyme-linked immunosorbent assay plates were coated over-
night at 4°C with 5 µg/ml of antigen in PBS or PBS only. Blocking 
was done for 1 h at room temperature (RT) with 1% milk 1% 
BSA/PBS (W/V). This was done to exclude possible “sticky” 
binders to plastic or non-specific binders to BSA/milk. Washing 
steps included 3× PBS/0.05% Tween-20 and 3× PBS. A total of 
50 µl of transgenic mouse serum were diluted in PBS (for initial 
testing of immunized animals), or supernatants from HEK 293T 
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cells were mixed with 50  µl of 2% milk 2% BSA/PBS (W/V) 
and incubated for 1 h at RT. After washing, the antigen-specific 
serum/supernatants were detected by incubation with goat 
antihuman IgG Fc coupled to horse radish peroxidase (HRP; 
Jackson Immuno Research Laboratories, Inc., USA) diluted 
1:5,000 for 1 h at RT, followed by washing steps and incubation 
with peroxidase substrate BM Blue POD (Roche Diagnostics 
GmbH, Germany). The reaction was stopped with 1M H2SO4, 
and the absorption was measured at 450 nm (against reference 
wavelength 690 nm).
For the initial testing of immunized WT and 4HVH trans-
genic mice sera for the presence of antigen-specific mouse 
antibodies, polyclonal goat antimouse immunoglobulins, HRP 
(Dako, Denmark) diluted 1:2,000 was used.
Sequencing
Sequencing of the positive DNA clones was done using primer 
CAG seq2-s 5′-GCTGGTTATTGTGCTGTCTCATC-3′.
Initial Affinity Measurement Screen and 
Full Kinetics
Medium was collected from HEK 293T cells, stably transfected 
with an HCAb expression vector and grown to confluence. To 
screen for the clones that expressed the highest affinity HCAb 
for HA, 200 µl of HEK 293T cell medium from each clone was 
transferred to a single well of a black 96-well microtiter plate 
(Greiner Bio-One, Germany). The binding of the HCAbs to 
influenza HA was studied using the Octet QK (ForteBio, USA). 
Anti-human IgG-coated tips (ForteBio, USA) were incubated 
with PBS/0.05% Tween-20 (120 s) to establish baseline signals. 
To allow the capturing of HCAbs, the tips were then transferred 
to 200 µl HEK 293T medium containing HCAbs (600 s), HEK 
293T medium without HCAbs and PBS/0.05% Tween-20 as 
a reference. Subsequently, the tips were transferred to 200  µl 
PBS/0.05% Tween-20 (480 s) to establish the binding levels after 
the dissociation of non-specific interactions. Next, the loaded tips 
were transferred to 200 µl 512 nM bromelain-released HA (BHA; 
600 s) to allow HA binding to the captured anti-HA HCAbs and 
to 200  µl PBS/0.05% Tween-20 (1,200  s) to determine the dis-
sociation rate of the HA from the HCAb.
The reference binding signal was subtracted from the binding 
curves, and the binding data were fitted to a 1:1 binding model 
using Octet 4.0 software. The HCAb clones that showed binding 
in initial affinity screen were selected for further analysis.
Full kinetics experiments were performed with purified 
HCAbs dialyzed against PBS. Anti-human IgG(Fc) sensors were 
dipped for 180 s in PBS/0.05% Tween 20. HCAb (10 µg/ml) was 
used for the loading step (300 s, 900 rpm), followed by 180 s in 
PBS/0.05% Tween 20. The association step with HA ligand in a 
concentration range from 0 to 512 nM was performed (600 s at 
900 rpm), followed by dissociation step of 1,200 s in PBS/005% 
Tween 20 at 900 rpm. All steps were done in 200 µl volume. The 
buffer only well (PBS/0.05% Tween 20) was used as a reference 
well. The reference binding signal was subtracted from the bind-
ing curves, and the binding data were fitted to a1:1 binding model 
using Octet 7.1 software.
production and purification of Anti-hA 
hcAbs
Positive clones were further expanded in medium contain-
ing 10% FCS. Alternatively, plasmid DNA was linearized 
with HindIII, stably transfected into HEK293T cells, and 
individual clones picked for the purpose of selecting the best 
expressors.
For production purposes, clones were grown in 15  cm 
Petri dishes in 25  ml of OPTI-MEM® (1×) + GlutaMAX™ 
(Gibco by Life technologies, CA, USA) medium. Medium 
was collected and replaced twice per week. Collected medium 
was spun down at 1,000  rpm (Eppendorf centrifuge 5810R) 
for 5 min to remove cell debris, and HCAbs were purified on 
Protein A agarose Fast Flow 50% (V/V; Sigma, USA). A total 
of 100  µl of Protein A beads were incubated with 50  ml of 
medium  overnight at 4°C on a rotating wheel. After spinning at 
1,000 rpm for 5 min, beads were washed in PBS/0.01% Tween-
20 and loaded onto homemade columns (insulin syringe with 
cotton wool), washed 3× with PBS/0.01% Tween-20, 3× with 
PBS, and eluted with 3M potassium thiocyanate (KSCN). 
Eluted HCAbs were dialyzed for 5–6  h using Spectra/Por 
dialysis membrane MWCO 10000 (Spectrum Laboratories 
Inc., USA) against 1,000× volume excess of PBS at 4°C. The 
procedure was repeated three times.
production and purification of Vh 
Domains in E. coli
VH domains from HCAbs were cloned without a tag into pET 
SUMO vector (Champion pET SUMO Expression system, 
Invitrogen, CA, USA). Production of fusion protein, cleavage, 
and removal of SUMO and SUMO protease were done accord-
ing to the manufacturer’s instruction with recommended 
reagents.
VH domains in fusion with SUMO were purified from inclu-
sion bodies starting with 200 ml BL21 transfected cells after 4 h 
of induction (1 mM IPTG). Cells were harvested, pellet frozen 
overnight, and lysed in 20 ml lysis buffer (50 mM KPO4, pH 7.8; 
400 mM NaCl; 10 mM KCl; 10% glycerol; and 0.5% Triton X-100). 
After sonication 20 × 20 s ampl 12 and spinning for 15 min at 
4,000  rpm at 4°C, pellet was taken in 1  ml PBS with addition 
of 10 µl benzonase for 30 min at RT. After washing in washing 
buffer (100  mM Tris pH 7.5; 5  mM EDTA; 2  M urea; and 2% 
Triton X-100), sample was spun for 15 min at 4,000 rpm, washed 
2× in 10  ml of 100  mM Tris pH 7.5 and 5  mM EDTA. Pellet 
was taken into 8 M urea; 10 mM Tris pH 7.5; and 2 mM DTT, 
rotated for 2 h at RT, spun for 30 min, 15,000 rpm at 4°C, and the 
supernatant was used in refolding. Base refolding buffer 2 from 
Pierce refolding kit was used (440 mM 1-arginine; 55 mM Tris 
pH 8.2; 21 mM NaCl; and 0.88 mM KCl). Protein was diluted to 
1 mg/ml; in 8 M urea, 10 mM Tris pH 7.5; and 2 mM DTT. To fold 
0.5 mg of protein, we used 9 ml base refolding buffer, 100 µl 0.1 M 
EDTA, 6.75  mg GSH (reduced glutathione), 2.65  mg of GSSG 
(oxidized glutathione), and H2O up to 9.5 ml. Protein was added 
in 50 µl aliquots, well mixed, and left on ice for at least 1 min 
after each addition. After overnight incubation at 4°C, sample was 
dialyzed against PBS buffer.
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Solubility Test and Fplc
A total of 500  µg of each HCAbs was concentrated to an end 
point of 30  µl volume using Centriprep-10  K centrifugal filter 
device (Merck Millipore Ltd., Ireland) as suggested by the 
manufacturer. Concentrated samples were diluted 10× in 8M 
guanidine hydrochloride (Gdn-HCl) and the OD at 280  nm 
measured on a NanoDrop 2000 spectrophotometer (Thermo 
Scientific, Ireland). The same procedure was used for selected 
VHs expressed in E. coli.
A total of 2 µg of purified and PBS-dialyzed HCAb in 50 µl of 
PBS was run on a Superdex 200 (3.2/30) column (GE HealthCare 
Life Sciences, USA) on the FPLC Smart system from Pharmacia. 
Samples were run in PBS. Bio-Rad’s gel filtration standard as a 
mixture of molecular weight markers ranging from 1,350 to 
670,000 Da was used as a control. The same procedure was done 
with selected VHs expressed in E. coli run on a Superdex 75 
(3.2/30) column (GE HealthCare Life Sciences, USA).
Virus Reduction Assay
The microtiter plaque reduction assay, as described by 
Matrosovich et  al. (18), was performed using MDCK-SIAT1 
cells. Twofold dilutions of the HCAbs were incubated on cell 
monolayers prior to addition of virus. The neutralization titer 
is determined as the reciprocal of the dilution of HCAbs, which 
corresponds to 50% reduction in plaque formation, compared to 
the virus control.
hemagglutination Inhibition (hI) Assay
Hemagglutination inhibition assays were performed according to 
standard methods, Kendall et al. (19), using 0.75% and 1.0% of 
Turkey and guinea pig red blood cell suspensions, respectively. 
Four HA units and twofold dilutions of HCAbs were used in these 
assays. HI titers are reciprocals of the highest dilution of HCAbs, 
which inhibited hemagglutination.
ReSUlTS
4HVH transgenic mouse lines contain four non-mutated human 
germ line heavy variable regions (VH3-11, VH3-23, VH3-53, and 
VH1-46) followed by all human D and J regions, the Cγ2 and Cγ3 
constant regions, each with a deleted CH1 exon and the human 
immunoglobulin 3′LCR (Figure 1). All transgenic mouse lines 
rearranged the human HCAb locus and rescued B cell develop-
ment in a mouse Cμ knockout background (20). They express 
HCAb dimers in the serum of the correct size (75–90 kDa). These 
mice were immunized and used as a source of antigen-specific 
antibodies in developing the method of cloning HCAbs directly 
into mammalian cells.
Immunization of Transgenic Mice leads to 
Successful production of Antigen-Specific 
hcAbs
A total of 20 or 50 µg of influenza X-31 HA protein, prepared as 
described by Ruigrok et al. (17), per mouse was injected intra-
peritoneally in 2 weeks intervals into eight of 4HVH transgenic 
mice (two transgenic lines, 4HVH-B and 4HVH-C, originating 
from different founders, having different integration site of the 
transgene) and two WT mice as a control, using Stimune as an 
adjuvant. After the third injection, mice were bled, and an ELISA 
assay was performed on serum, using HA protein-coated plates 
(5  µg/ml) and anti-human IgG-HRP or anti-mouse IgG-HRP 
for the detection of HA-specific antibodies. In seven out of eight 
transgenic mice and two out of two WT mice, HA-specific anti-
bodies were detected (Figure S1 in Supplementary Material). The 
higher amount of antigen did not lead to a better response, thus 
we concluded that 20 µg is sufficient for successful immunization. 
Seven transgenic ELISA positive mice were immunized three or 
more times with 20 µg of HA.
heK 293T hcAbs library construction 
and Subsequent Screening Result in a 
Diverse Repertoire of Antigen-Specific 
Soluble Antibodies
Four days after the last injection without adjuvant, mice were 
sacrificed, and CD 138+ PCs were isolated from bone marrow 
and spleen. Total RNA was isolated, and cDNA was synthesized 
(depicted schematically in Figure  1). Human VDJ domains 
were amplified using a set of three different 5′-end primers 
specific for the leader sequences in the transgenic mouse 
construct in combination with two different 3′-end primers 
specific for either the human IgG2 or IgG3 hinge (3). Due to 
the high sequence similarity, the same 5′-end primer was used 
for amplification of both VH3-23 and VH3-53. All 5′-primers 
were designed to contain a PvuII restriction site. A PvuII site 
appears usually at the beginning of the DNA encoding VH 
regions (third to fourth codons at the amino acid level) and 
rarely occurs anywhere else in human VHs. Amplified PCR 
products were cut either with PvuII/SacI or with PvuII/BstEII 
restriction enzymes. The SacI site is a unique site at the begin-
ning of the IgG3 hinge, while the BstEII site in frame 4 is unique 
in most of the VHs and is commonly used for constructing 
phage libraries (21, 22).
The VDJ fragments were cloned into bacteria using either 
pCAGhygro G2 or pCAGhygro G3 expression vectors, contain-
ing the ubiquitously expressed chicken β-actin promoter, the 
leader sequence from human VH3-23, and the constant region of 
human IgG2 or IgG3 (Figure 2). The ligated cDNA was transfected 
into electrocompetent E. coli cells, totaling 1 part out of almost 
700,000 of the available RNA in the mice (PCs were isolated from 
half of the total number of cells, 1/4 of total RNA was made into 
cDNA, 1/30 of the gel purified PCR amplified cDNA was used 
in the ligations; 1/50 of the ligation was transformed, 1/32 of 
the transformed bacteria was plated, and 0.57 of total colonies 
counted were picked from those plates). A total of 960 colonies 
were picked from both the G2 and G3 library into 96-well plates 
filled with 2XTY medium. The resulting recombinant bacteria 
were grown overnight, and plasmid DNA was prepared in the 
same 96-well format. In parallel, HEK 293T cells were also grown 
in a 96-well format and transfected with the plasmid DNA main-
taining the same 96-well format. A 96-well HA-specific ELISA 
FIgURe 3 | Sequence analysis of hemagglutinin X-31 elISA positive clones showing a broad range of diversity based on somatic mutations (black 
boxes) and cDR3 loops (blocks of different colors). The columns on the right show the number of times a particular sequence was found, whether it tested 
positively on Octet and which J region was used. Yellow shading at the carboxy-terminal end of the sequence shows an IgG3 sequence (LKTPLG), the others are 
IgG2 (RKCCVE).
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screen was performed with supernatants from each well 4 days 
after transfection. This yielded 66 positive supernatants/clones. 
The corresponding cDNAs were sequenced (Figure  3), which 
showed that two out of the four available variable segments were 
used preferentially (VH3-11 and VH3-23); the VDJ domains 
contained somatic hypermutations; J4 was predominantly used 
but J5 and J6 were also found; both IgG2 and IgG3 antibodies 
were present, confirming that class switching occurred in the 
transgenic mouse. Most prevalent are IgG2 HCAbs, and it is not 
surprising taking into account that the IgG2 constant region is 
the most proximal in the transgenic construct and thus the first 
to recombine. Out of 66 sequences, 45 were unique and these 
account for 33 different DJ regions. Based on the different CDR3 
regions, the HCAbs were classified into 13 distinct groups repre-
sented in different colors (Figure 3). Positive clones were cultured 
further, and supernatants were collected for affinity screening, 
using the same HA antigen preparation. Twenty four clones 
showed significant binding. A selected number of clones (based 
on sequence diversity and affinity) were produced in serum free 
medium. The antibodies with low affinities were not tested at all 
in a functional assay (see below). Four groups represented by 7F2 
(Figure 3, blue), 2F4 (green), 1F3 (red), and 3A8 (yellow) were 
left. Of these, 1F3 and 2F4 appear to bind the same epitope(s), 
while 3A8 and 7F2 appear to bind a different but overlapping 
epitope(s).
characterization of Anti-hA Antibodies
Heavy-chain-only antibodies from medium were purified on pro-
tein A, eluted in 3M KSCN, and dialyzed against PBS. The average 
yield was estimated to be 2–4 µg/ml of medium. On SDS-PAGE 
gel, HCAbs are of expected size for a monomer (~40–45 kDa) 
under reducing and of a dimer (~80–90 kDa) under non-reducing 
conditions (Figure 4A). Size differences originate from different 
sizes and compositions of VH regions and different sizes (longer 
hinge) of IgG3 HCAbs, accounting for >5  kDa difference per 
monomer in comparison to IgG2 HCAbs. The profiles on size 
chromatography (smart columns) showed a single peak of the 
expected size; the peaks of the IgG3 HCAbs, 3A11, and 3B10 
were of higher molecular weight than IgG2 HCAbs (Figure 4B). 
Solubility in PBS was tested with 500 µg of each HCAb by con-
centrating it to ~30 µl of final volume. The selected HCAb differed 
with concentrations up to 15.4 µg/µl for 1F1, the equivalent of 
30  mg/ml of a normal H2L2 antibody (Figure  4C). Further 
concentration of the very soluble antibodies was not tested. Two 
of the VHDJ segments (3A8 and 2F4) were also expressed in 
bacteria and shown to be soluble in at least 5 mg/ml, which is 
FIgURe 4 | characterization of heavy-chain-only antibodies (hcAbs). (A,B) An example of SDS-PAGE gels run under non-reducing conditions (A) and 
reducing conditions (B) shows that HCAbs form dimers. (c) HPLC SMART profiles show a single peak for each antibody, the solubility and affinity measurements for 
selected HCAb clones. Note that 3A8 and 3B10 are IgG3 HCAbs and are of higher molecular weight due to a longer hinge region.
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also equivalent to 30 mg/ml of a normal H2L2 antibody (Figure 
S2 in Supplementary Material). Binding affinities of the HCAb 
were determined on an Octet instrument with purified antibod-
ies. A BHA preparation (23) that lacks a transmembrane anchor 
was used to prevent rosette formation and aggregation of antigen. 
The majority of KD values (9 of 17) for HCAbs were in the 10−9 
molar range, 7 were in the 10−8 molar range, while the KD value 
for the highest affinity 1F3 HCAb was better than 10−10. HCAbs 
1G7, 1G11, 2F4, 1F4, 1C12, 4H1, and 3A11 react on Western blots 
under both non-reducing and reducing conditions recognizing 
denatured BHA monomer and the BHA1 chain, respectively. 
7F2 reacts with BHA only under non-reducing conditions, while 
1F3 preferentially recognizes BHA1 under reducing conditions 
(data not shown).
Anti-hA hcAbs Function in Virus 
neutralization and hI
The HA HCAbs were first evaluated for their ability to neutral-
ize X.31 (H3N2) influenza virus in a plaque reduction assay. 
Neutralization is reported as the reciprocal of the highest dilution 
of the antibodies corresponding to 50% plaque reduction com-
pared to the virus control. A total of 18 of the antibodies tested 
show visible inhibition, and 50% reduction is observed for four 
HCAb, 1F3 > 2F4 > 3A8 > 4H1 = 7F2 (Table 1). A modified 
neutralization experiment was also performed, where antibodies 
were incubated for 30  min with the virus prior to addition to 
MDCK-SIAT1 cells. This led to an increased neutralizing effect 
especially in the case of 2F4 and 1F3 antibodies [2F4 neutralizing 
at ≥1.4 µg/ml (18nM) and 1F3 at ≥0.9 µg/ml (11.7nM)]. Ferret 
FIgURe 5 | hemagglutination inhibition assay performed on Turkey 
red blood cells. 3A8 and 7F2 HCAbs inhibit at a concentration of 
0.0075 mg/ml (84 nM) and 0.0375 mg/ml (483 nM), respectively.
TABle 1 | neutralization analysis of heavy-chain-only antibodies (hcAbs) against X-31 influenza virus.
nI I nI I nI I nI I nI nI nI
HCAbs 2F4 2F4 1F3 1F3 3A8 3A8 4H1 4H1 7F2 HC19 X31
Concentration (mg/ml) 0.85 0.9 1.2 1.2 0.48 0.55 1.6 0.8 0.4 NK NK
X31(50% reduction) 32 640 >256 >1,280 16 20 2 2 2 6,400 2,560
X31 (any visible reduction) 64 >1,280 >256 >1,280 64 160 2 8 64 >12,800 >5,120
The numbers show best neutralizing capacity for 1F3 HCAb at ≥0.9 μg/ml (~11nM), followed by 2F4 at 1.4 µg/ml (~18nM).
NI, not preincubated with the virus; I, preincubated with the virus; NK, not known; neutralization titer, reciprocal of the 50% plaque reduction.
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anti X-31 serum and HC19, an anti-X31 HA mouse monoclonal 
antibody, were used as positive controls. 3A8 and 7F2 HCAbs also 
showed an HI performed with Turkey red blood cells (Figure 5) 
and with guinea pig blood (data not shown), suggesting that 3A8 
and 7F2 neutralize infectivity by obstructing the binding of virus 
to the host cell.
DIScUSSIon
Here, we describe a very efficient method for obtaining fully 
human, antigen-specific, soluble, high-affinity HCAbs, which 
can easily be automated. Our approach is based on capturing the 
antibody repertoire of antibody-secreting PCs from both bone 
marrow and spleen of immunized transgenic mice. Recently, 
other laboratories have used mouse spleen PCs (24), mouse 
bone marrow PCs (25), human peripheral blood PCs (26, 27), 
or human MBC from patient recovered from infection (28) to 
obtain antigen-specific monoclonal antibodies. Basically, those 
methods utilize single-cell sorting, single-cell RT-PCR, and 
natural VH–VL pairing (27, 28). Screening methods have been 
developed to improve efficiency and enable detection of antigen-
specific secreting cells before a single-cell RT-PCR step, such as 
enzyme-linked immunospot (29), immunospot array assay on 
chip or microengraving (30). Recently, a method was described 
(24) omitting a screening step, utilizing massive DNA sequencing 
and bioinformatics tools to analyze the VL and VH gene reper-
toires and to find several abundant VH and VL sequences that 
are paired based on their relative frequencies with 78% efficiency 
and a method that combines the next-generation sequencing and 
protein mass spectroscopy to obtain antigen-specific antibody 
repertoires (31). DeKosky and colleagues developed a low-cost, 
single-cell, emulsion-based technology for sequencing of anti-
body VH–VL repertoires with even better pairing precision of 
>97% (32).
The 4HVH transgenic mice produce human HCAb, without 
light chains, thus there is no pairing or the necessity for single-
cell RT-PCR. The major concern was the solubility of human 
VH domains, that are not soluble per se, but as our results show, 
antigen-specific HCAbs selected through our screen show high 
solubility both as a full-length HCAbs and as VH fragments only, 
thus, the method allows easy isolation of soluble VH regions and 
the construction of multivalent soluble VH complexes.
The soluble human VH domains obtained from transgenic 
mice presented here do not possess the hallmark amino acid 
changes present in VHHs of camelid HCAbs (at positions 44, 
45, and 47), which reduce the hydrophobicity of the former light 
chain interface. They remain as germ line VH being G, L, and W, 
respectively. As for replacing the V 37 of VH by more hydrophilic 
F or Y in VHHs, 1 out of 66 VH domains have mutated at this 
position to F 37, one to L 37. All V3-11-derived HCAbs have I-37 
as in the germ line. We have analyzed many sequences from differ-
ent immunizations with different antigens, beyond the restricted 
list of anti HA HCAbs shown in Figure  3. We have seen FR2 
substitutions, which are not found in antibodies that comprise 
heavy and light chain. We found an increased net hydrophobicity 
within CDR1 and an increased number of charged amino acids 
present in CDR3, amino acid substitutions within the framework 
β-pleated sheet leading to increased net hydrophobicity within 
FR1, and increased number of charged amino acids present in 
FR3, all of which could lead to solubility of autonomous soluble 
VH domains obtained from transgenic mice (33).
This experiment was done in 4HVH transgenic mice bred 
into our own Cμ MT heavy chain knockout background. It was 
previously reported that Cμ MT knockout mice can produce low 
levels of IgG antibodies after prolonged time (34). In such a case, 
mouse light chains might theoretically attach to the human VHs 
and affect their solubility, which could cause a problem in using 
hybridoma fusions. If the reason for increased solubility is light 
chain attachment, the solubility will be hampered by cloning the 
heavy chain only (VH) in expression vectors. Once produced, 
such antibodies would have aggregation problems, which we do 
not see using HEK 293T libraries. Knocking out the loci com-
pletely would avoid the problem.
The choice of VHs in the transgenic construct was based on 
the VH usage in a human population. It is also known that soluble 
llama VHHs mostly resemble family three of human VHs (6). 
The fact that in this particular experiment most of the obtained 
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antibodies originated from VH3-11, a few fromVH3-23, while 
none from V3-53 and VH1-47 could be explained by antigen-
related specific usage. A new class of influenza-neutralizing anti-
bodies that target a conserved site in the HA stem, most of them 
being VH 1-69, have been described, but this VH is not present 
in our transgenic mouse (35). In other experiments, the other VH 
regions are also used (data not shown). The soluble human VH 
domains obtained from transgenic mice presented here do not 
possess hallmark amino acid changes present in VHHs of camelid 
HCAbs (at positions 44, 45 and 47), which function to reduce 
hydrophobicity of the former light chain interface. They remain 
as in germ line VH situation being G, L, and W, respectively.
The four human VHs obtained from transgenic mice were 
cloned into human IgG2 and IgG3 vectors to reproduce char-
acteristics of antibodies circulating in transgenic mouse. For 
most therapeutic purposes, human IgG1 and IgG4 antibodies are 
preferred, due to their effector functions. Once obtained, selected 
VHs could be cloned and expressed as human IgG1 or IgG4 in 
appropriate vectors.
We are improving our transgenic mouse platform by increasing 
the numbers of germ line VHs in the construct, thus increasing 
the repertoire. The human constant regions in the new generation 
of transgenic mice have been replaced by the mouse constant 
region/s reported to be better suited to the mouse machinery 
(36), while direct cloning might be performed into human IgG 
vectors of choice.
The pilot experiment performed with 960 plasmid DNAs from 
the bacterial library and an estimated 7% vector contamination 
(plasmids without the cDNA insert) gave 66 ELISA-positive 
clones, 45 of these being unique. If we take into account that 
the mice carry only 4VH regions, that only a tiny fraction of the 
available material was used, and that 83% of retrieved antibody 
sequences were represented only once in the sample tested, a very 
high efficiency of obtaining many more high-affinity antibodies 
in an industrial scale automated/robotized process at low cost can 
be predicted.
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